What if we could use a cancer’s own byproduct to make drugs that destroy tumor cells from the inside? That is what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan.
Related Posts
Sequential nonarteritic anterior ischemic optic neuropathy occurs earlier with GLP-1 receptor agonist exposure
Credit: Mizuno K from Pexels For patients with nonarteritic anterior ischemic optic neuropathy (NAION), glucagon-like peptide-1 (GLP-1) receptor agonist exposure is associated with earlier sequential […]
People are taking an unapproved weight-loss drug. AI found something surprising
An experimental weight-loss drug that has not yet received regulatory approval is already attracting users willing to obtain unapproved versions online. Now, scientists are using […]
‘Art Has Gotten Me Through Chronic Pain. Here’s How’
Encouraging people to express pain through art is the core of the nonprofit, says Kimel. The Chronic Pain Project has participants all over the country […]